(CYBN) Cybin - Ratings and Ratios
Psychedelic Therapeutics, Psilocybin Analog, DMT Derivative, Depression, Anxiety
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 103% |
| Value at Risk 5%th | 141% |
| Relative Tail Risk | -16.89% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.31 |
| Alpha | -50.63 |
| CAGR/Max DD | -0.16 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.338 |
| Beta | 1.086 |
| Beta Downside | 0.586 |
| Drawdowns 3y | |
|---|---|
| Max DD | 79.66% |
| Mean DD | 49.74% |
| Median DD | 54.10% |
Description: CYBN Cybin October 29, 2025
Cybin Inc. (NYSE MKT: CYBN) is a Toronto-based, clinical-stage biotech that pursues psychedelic-derived medicines for mental-health disorders. Its lead assets are CYB003, a deuterated psilocybin analog currently in a Phase 3 trial for major depressive disorder (MDD), and CYB004, a deuterated DMT in Phase 2 for generalized anxiety disorder. Additional programs include SPL028 (completed Phase 1 intramuscular/intravenous DMT), SPL026 (MDD), and CYB005 (a phenethylamine derivative in pre-clinical development). The firm has partnered with Segal Trials to run the multinational PARADIGM Phase 3 study of CYB003 as an adjunctive MDD therapy.
Key external factors that could materially affect CYBN’s valuation: (1) the global psychedelic-therapy market is projected to exceed $10 billion by 2030, driven by shifting regulatory attitudes and rising demand for novel psychiatric treatments; (2) as of the latest 10-Q, Cybin reported cash and cash equivalents of roughly $45 million, giving it an estimated 12-month runway assuming current burn rates, but this assumes no major cost overruns in Phase 3; (3) the broader biotech sector is sensitive to interest-rate cycles-higher rates increase the discount rate applied to long-duration R&D projects, which could compress equity multiples for early-stage firms like CYBN. These drivers are highly uncertain: trial outcomes, regulatory approvals, and financing conditions could all diverge sharply from current expectations.
If you want a data-rich, unbiased view of how these variables translate into a price target, a quick look at ValueRay’s analyst toolkit can help you model different scenarios without any promotional bias.
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.63 (>2.0%) and ΔFCFTA -24.67pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.62 (>3.0%) and CFO -112.3m <= Net Income -99.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (24.2m) change vs 12m ago 21.00% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.80 (EBITDA TTM -84.6m / Interest Expense TTM 14.6m) >= 6 (WARN >= 3) |
Altman Z'' -2.95
| (A) 0.56 = (Total Current Assets 114.6m - Total Current Liabilities 13.4m) / Total Assets 181.2m |
| (B) -1.65 = Retained Earnings (Balance) -299.9m / Total Assets 181.2m |
| warn (B) unusual magnitude: -1.65 — check mapping/units |
| (C) -0.38 = EBIT TTM -84.8m / Avg Total Assets 221.8m |
| (D) 1.29 = Book Value of Equity 54.5m / Total Liabilities 42.2m |
| Total Rating: -2.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.14
| 1. Piotroski 0.0pt |
| 2. FCF Yield -32.15% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.21 |
| 5. Debt/Ebitda 0.65 |
| 6. ROIC - WACC (= -41.23)% |
| 7. RoE -51.79% |
| 8. Revenue Trend data missing |
| 9. EPS Trend -70.41% |
What is the price of CYBN shares?
Over the past week, the price has changed by +11.52%, over one month by +3.41%, over three months by +9.69% and over the past year by -33.47%.
Is CYBN a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CYBN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 47.7 | 613.8% |
| Analysts Target Price | 47.7 | 613.8% |
| ValueRay Target Price | 5.7 | -14.5% |
CYBN Fundamental Data Overview December 12, 2025
P/S = 278.2498
P/B = 2.064
Beta = 1.092
Revenue TTM = 0.0 CAD
EBIT TTM = -84.8m CAD
EBITDA TTM = -84.6m CAD
Long Term Debt = 28.9m CAD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 28.9m CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = -54.9m CAD (from netDebt column, last quarter)
Enterprise Value = 355.6m CAD (410.4m + Debt 28.9m - CCE 83.8m)
Interest Coverage Ratio = -5.80 (Ebit TTM -84.8m / Interest Expense TTM 14.6m)
FCF Yield = -32.15% (FCF TTM -114.3m / Enterprise Value 355.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 118.1m) / Revenue TTM)
Tobins Q-Ratio = 1.96 (Enterprise Value 355.6m / Total Assets 181.2m)
Interest Expense / Debt = 0.43% (Interest Expense 124.0k / Debt 28.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -67.0m (EBIT -84.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.58 (Total Current Assets 114.6m / Total Current Liabilities 13.4m)
Debt / Equity = 0.21 (Debt 28.9m / totalStockholderEquity, last quarter 139.0m)
Debt / EBITDA = 0.65 (negative EBITDA) (Net Debt -54.9m / EBITDA -84.6m)
Debt / FCF = 0.48 (negative FCF - burning cash) (Net Debt -54.9m / FCF TTM -114.3m)
Total Stockholder Equity = 192.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -54.87% (Net Income -99.5m / Total Assets 181.2m)
RoE = -51.79% (Net Income TTM -99.5m / Total Stockholder Equity 192.0m)
RoCE = -38.39% (EBIT -84.8m / Capital Employed (Equity 192.0m + L.T.Debt 28.9m))
RoIC = -31.85% (negative operating profit) (NOPAT -67.0m / Invested Capital 210.4m)
WACC = 9.38% (E(410.4m)/V(439.3m) * Re(10.02%) + D(28.9m)/V(439.3m) * Rd(0.43%) * (1-Tc(0.21)))
Discount Rate = 10.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -56.39%
Fair Price DCF = unknown (Cash Flow -114.3m)
EPS Correlation: -70.41 | EPS CAGR: -15.41% | SUE: -0.06 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS current Year (2026-03-31): EPS=-4.29 | Chg30d=-0.016 | Revisions Net=-1 | Growth EPS=+23.3% | Growth Revenue=+0.0%
EPS next Year (2027-03-31): EPS=-4.03 | Chg30d=+0.788 | Revisions Net=+1 | Growth EPS=+6.0% | Growth Revenue=+0.0%
Additional Sources for CYBN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle